Athersys ($ATHX): Another Patent, GvHD
Monday, April 16, 2012 at 11:16AM
DDE Editor in Regenerative Medicine, athx

Athersys has obtained a U.S patent for its MultiStem technology, a stem cell treatment for graft-versus-host disease that employs cells from adult bone marrow and other nonembryonic sources. The product has shown the ability to limit inflammation, protect impaired tissue and aid in the formation of new blood vessels.

See the full press release.

View the full ATHX chart at Wikinvest
Article originally appeared on Daily Dose Equities - Wall Street Analysis for Biomedical Research (http://dailydoseequities.filmannex.com/).
See website for complete article licensing information.